Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

175 results about "Galectin" patented technology

Galectins are a class of proteins that bind specifically to β-galactoside sugars, such as N-acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc), which can be bound to proteins by either N-linked or O-linked glycosylation. They are also termed S-type lectins due to their dependency on disulphide bonds for stability and carbohydrate binding. There have been 15 galectins discovered in mammals, encoded by the LGALS genes, which are numbered in a consecutive manner. Only galectin-1, -2, -3, -4, -7, -8, -9, -10 and -12 have been identified in humans. Galectin-5 and -6 are found in rodents, whereas galectin-11, -14 and -15 are uniquely found in sheep and goats. Members of the galectin family have also been discovered in other mammals, birds, amphibians, fish, nematodes, sponges, and some fungi. Unlike the majority of lectins they are not membrane bound, but soluble proteins with both intra- and extracellular functions. They have distinct but overlapping distributions but found primarily in the cytosol, nucleus, extracellular matrix or in circulation. Although many galectins must be secreted, they do not have a typical signal peptide required for classical secretion. The mechanism and reason for this non-classical secretion pathway is unknown.

Methods of treating inflammatory diseases by blocking Galectin-3

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.
Owner:TRUEBINDING INC

Antibody or antigen binding fragment thereof and application thereof

The invention provides a target antibody or an antigen binding fragment thereof and application thereof, and belongs to the field of antibodies. Wherein the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR, and the HCDR comprises at least one selected from SEQ ID NO: 1-18 or an amino acid sequence having at least 80% homology with the HCDR. The antibody or the antigen-binding fragment thereof can bind to TIM-1 protein with high specificity and affinity, increase the blocking of TIM-1 activity so as to enable the TIM-1 to interact with ligands such as phosphatidylserine, TIM-4 and galectin-9, and enhance immune response.
Owner:UNIV OF SCI & TECH OF CHINA

Combined medicine for preventing and / or treating prostatic cancer, application of combined medicine and pharmaceutical composition

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Galectin-10 antibodies

The present invention relates to antibodies and antigen binding fragments thereof that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antibodies and antigen binding fragments of the invention, disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation / presence of Charcot-Leyden crystals (CLCs).
Owner:ARGENX BVBA(BE)

Detection reagent and kit for eosinophilic granulocyte chronic sinusitis with nasal polyp

The invention belongs to the technical field of biology, and particularly relates to a reagent and a kit for detecting eosinophilic granulocyte chronic sinusitis with nasal polyp. The detection reagent comprises the following components: a substance which is used for detecting the Galectin-10 protein (Charcot-Leyden Crystal, CLCs) in a crystalline state, and a detection reagent which is used for detecting the Galectin-10 protein (Charcot-Leyden Crystal, CLCs) in the crystalline state. The reagent for detecting CLCs comprises a mixture of eosin, glacial acetic acid and water. The mass volume ratio of eosin to glacial acetic acid is 1: (1-50) g / mL, and the volume ratio of glacial acetic acid to water is 1: (2-100). According to the invention, the reagent capable of efficiently detecting the CLCs is found for the first time, and the CLCs is a biomarker of the eosinophilic chronic sinusitis with nasal polyp, so that the detection reagent for the eosinophilic chronic sinusitis with nasal polyp is provided. By detecting CLCs, eosinophilic granulocyte chronic sinusitis with nasal polyp can be predicted, and the method is simple, convenient and fast and has good prediction performance.
Owner:THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIV +1

Galactoside inhibitor of galectins

The present invention relates to a D-galactopyranose compound of formula (1)whereinthe pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and / or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders.
Owner:GALECTO BIOTECH

Inhibition of endosomal escape detection to ameliorate the inflammatory side-effects of lipid nanoparticles

PCT designated stage expiredWO2025128913A1Powder deliveryTetrapeptide ingredientsSide effectMedicine
Composition and methods for preventing or reducing inflammation resulting from nanoparticle administration to a subject are provided. In one embodiment a method of delivering an agent to a target organ of a subject, comprises administering to the subject a galectin inhibitor and a nanoparticle comprising the agent, wherein inflammation resulting from administration of the nanoparticle is reduced or prevented.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Anti-galectin-9 antibodies and uses thereof

Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.
Owner:NEW YORK UNIV +1

Anti-gal3 antibodies and methods of use

Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and / or proteins associated with neurological diseases and / or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and / or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
Owner:TRUEBINDING INC

Application of Galectin-3 glycosylation inhibitor in preparation of drugs for resisting esophageal cancer angiogenesis

The invention discloses an application of a Galectin-3 glycosylation inhibitor in preparation of an anti-esophageal cancer angiogenesis medicine, and belongs to the technical field of biological medicines. The invention particularly relates to application of a reagent for promoting mutagenesis of an O-GlcNAc modification site of Galectin-3 in preparation of a medicine for resisting tumor angiogenesis. The Galectin-3 is obviously higher in serum of an esophageal cancer patient than a healthy control, the glycosylation modification level of Galectin-3 in esophageal cancer cells is changed through molecular biology means such as construction of Galectin-3 specific plasmids and the like, it is found for the first time that interference on Galectin-3 glycosylation modification can obviously inhibit esophageal cancer cell angiogenesis mimicry, and therefore the Galectin-3 can be used for inhibiting esophageal cancer cell angiogenesis mimicry. The Galectin-3 glycosylated modified specific plasmid and other molecular biological means constructed by the invention can be applied to preparation, screening or treatment of esophageal cancer or inhibition of esophageal cancer angiogenesis, and a new treatment method is provided for intervention or treatment of esophageal cancer.
Owner:SOUTHEAST UNIV

A galectin 10 crystal and an antibody igy and a pharmaceutical preparation prepared therefrom

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.
Owner:SHANGHAI BIO-FULL BIOTECH CO LTD

Compound of Galectin-3 and EGFR double-target inhibitor and application thereof

The invention discloses a compound of a Galectin-3 and EGFR (Epidermal Growth Factor Receptor) double-target inhibitor in the technical field of biological medicines, and the compound disclosed by the invention not only shows a relatively strong Galectin-3 and EGFR binding effect, but also has certain in-vitro anti-hepatic fibrosis activity, and can be applied to Galectin-3 and EGFR target related tumor diseases. As a double-target anti-hepatic fibrosis candidate compound based on Galectin-3 and EGFR, which is reported for the first time, the compound has further values of research and development and research of original new drugs based on double targets of Galectin-3 and EGFR.
Owner:ZHONGSHAN INST FOR DRUG DISCOVERY SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1

USE OF Galectin-1 INHIBITOR IN PREPARATION OF DRUG FOR TREATING PULMONARY FIBROSIS

Provided is a use of a Galectin-1 inhibitor in preparation of a drug for treating pulmonary fibrosis. Taking silicosis model mice as a subject, administration of a Galectin-1 inhibitor OTX008 to silicosis mice can effectively alleviate the progression of pulmonary fibrosis. Studies have shown that the lung function of mice with silicosis is improved significantly; transcription levels of inflammatory factors Il-1β and Il-6 in the lung tissue of silicosis mice are decreased, concentrations of IL-1β and IL-6 in the alveolar lavage fluid are also decreased, and the infiltration of inflammatory cells is decreased. In the lung tissue of silicosis mice, the transcription levels of fibrosis factors Col-I and Fn-1 are decreased, the collagen-specific amino acid hydroxyproline is decreased, the fibrosis lesions are decreased, and the degree of lesions is alleviated. Therefore, the Galectin-1 inhibitor can be used as a new treatment strategy for pulmonary fibrosis.
Owner:INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES

Anti-galectin-9 antibody and its uses

The present invention provides a humanized monoclonal antibody against Gal9, and methods of using the antibody to treat cancer, including combination therapies with antagonists of the PD-1 / PD-L1 immune checkpoint.
Owner:HIFIBIO INC(US)

Nebulization of Fab fragments

The present invention relates to a method of treating a disease or disorder associated with the presence or formation of galectin-10 crystals, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a Fab fragment that binds to galectin-10, wherein the composition is administered as an aerosol. Also included in the invention is a pharmaceutical composition comprising a Fab fragment that binds to galectin-10, and a nebulizer comprising the pharmaceutical composition. The pharmaceutical composition may be useful for treating a disease or disorder associated with the presence or formation of galectin-10 crystals, such as asthma or cystic fibrosis.
Owner:ARGENX BVBA(BE)

Composition for preventing or treating lupus, comprising recombinant stabilized galectin 9 protein

The present invention relates to a composition for preventing or treating lupus or glomerulonephritis comprising a recombinant stabilized Galectin-9 protein. Specifically, the recombinant stabilized Galectin-9 protein of the present invention has been confirmed to exhibit safety in a systemic lupus erythematosus (SLE) animal model, reduce skin lesions, lymphadenopathy, and proteinuria caused by lupus, ameliorate lupus nephritis and glomerulonephritis, and decrease the concentration of anti-dsDNA antibodies in plasma. Accordingly, the recombinant stabilized Galectin-9 protein of the present invention can be effectively used as an active ingredient in a composition for preventing or treating lupus or glomerulonephritis.
Owner:GBIOLOGICS INC

Galectin MsGal-3 and application thereof in resisting MSRV infection in micropterus salmoides

The invention discloses a galectin MsGal-3 and an application of the galectin MsGal-3 in resisting MSRV infection in micropterus salmoides. Galectin MsGal-3 (the accession number is PV454561) is obtained through screening and identification from a liver transcriptome of micropterus salmoides, a target gene is synthesized, plasmids are constructed, then an escherichia coli E.coli expression strain BL21 is adopted for induced expression, and MsGal-3 protein is obtained through purification and can be used for preventing and treating micropterus salmoides rhabdovirus infection.
Owner:ZHEJIANG SCI-TECH UNIV

Use of cardiac troponin and galectin-3 to distinguish between type I and type II myocardial infarction

The present invention provides methods for determining whether a subject suspected of having a myocardial infarction is suffering from type I or type II myocardial infarction. In particular, systems and methods are provided that employ a probability score based on a decision tree-based algorithm to process the subject's gender, age, and cardiac troponin concentration, as well as the subject's galectin-3 (Gal-3) concentration.
Owner:ABBOTT LAB INC

Application of Galectin-3 inhibitor TD139 in treatment of tuberculous granuloma

The invention provides an application of a Galectin-3 inhibitor TD139 in the treatment of tuberculous granuloma. The TD 139 is proved to be a specific inhibitor of the Galectin-3, and the TD 139 is a specific inhibitor of the Galectin-3. According to the invention, the dosage of intraperitoneal injection of mice is 200 [mu] g / mouse. D <-1 >. By adopting the technical scheme of the invention to treat a mycobacterium marinum induced mouse tuberculosis model through the TD139, the formation of tuberculous granuloma is reduced in vivo through the TD139. TD139 is subjected to intraperitoneal injection once every other day and 5 times continuously, the granuloma area, the intracellular bacterium carrying amount and the inflammatory factor expression of the tail skin of a tuberculosis model can be remarkably reduced, and mice do not die in the whole process; the intrinsic mechanism is that PDIM is a toxic structure of a mycobacterium marinum bacterial wall and causes skin ulceration and granuloma. The Galectin-3 gene can inhibit phagocytosis and elimination of Mycobacterium marinum by macrophages and activation of innate immune pathways of the Mycobacterium marinum, and TD139 promotes the macrophages to eliminate pathogenic bacteria and reduces MMP-9 expression, so that formation of granuloma is reduced. The new pharmacological efficacy and the tuberculosis treatment mechanism of the TD139 are found for the first time, and a foundation is laid for future clinical application.
Owner:CHINA THREE GORGES UNIV

Pharmaceutical composition, comprising recombinant stabilized galectin 9 protein, for prevention or treatment of rheumatoid arthritis and bone disease

The present invention relates to a recombinant stabilized galectin 9 protein and the use thereof, and more specifically, relates to a pharmaceutical composition comprising the recombinant stabilized galectin 9 protein for prevention or treatment of rheumatoid arthritis and a bone disease. The recombinant stabilized galectin 9 protein differs from the wild-type galectin 9 protein in that the amino acids in the link region connecting two carbohydrates recognition domains (CRDs) are deleted, and the amino acids in the C-terminal CRD (CCRD) are deleted and substituted.
Owner:GBIOLOGICS INC

Modified Anti-galectin-9 antibody and uses thereof

Provided herein are affinity matured anti-galectin-9 (Gal9) antibodies. The antibodies have improved binding affinity to Gal9. Also provided herein are method of use of the affinity matured anti-Gal9 antibodies, including methods of treatment of cancer, methods of rescuing or promoting effector T cell proliferation, methods of enhancing effector T cell activity, and / or of identifying and treating cancer in a subject including the administration of the anti-Gal9 antibodies described herein. Also provided are polynucleotides encoding the heavy chain or the light chain or the antigen-binding portion thereof described herein, and vectors, especially expression vectors, including the polynucleotides described herein.
Owner:FIBROGEN INC +1

Use of cardiac troponin and galectin-3 for differentiating type I and type II cardiac infarction

The present invention provides methods for determining whether a subject suspected of having myocardial infarction is experiencing type I myocardial infarction or type II myocardial infarction. In particular, systems and methods are provided for processing the gender, age, and cardiac troponin concentration of a subject, as well as the galectin-3 (Gal-3) concentration of a subject, employing probability scoring based on a decision tree algorithm.
Owner:ABBOTT LAB INC